Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Public ClinicalTrials.gov record NCT04817618. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.
Study identification
- NCT ID
- NCT04817618
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 98 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 12 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 27, 2021
- Primary completion
- Jan 28, 2027
- Completion
- Jan 28, 2027
- Last update posted
- Jul 12, 2026
2021 – 2027
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Childrens Hospital Colorado | Aurora | Colorado | 80045 | Recruiting |
| Nicklaus Childrens Hospital | Miami | Florida | 33155 | Recruiting |
| Georgia Nephrology Research Inst | Lawrenceville | Georgia | 30046 | Completed |
| IN University School of Med | Indianapolis | Indiana | 46202-5111 | Withdrawn |
| University of Iowa Health Care | Iowa City | Iowa | 52242-1091 | Recruiting |
| University of Iowa Health Care | Iowa City | Iowa | 52242 | Recruiting |
| Johns Hopkins Hospital | Baltimore | Maryland | 21287 | Withdrawn |
| Brigham and Womens Hosp Harvard Med School | Boston | Massachusetts | 02115 | Withdrawn |
| Hackensack Uni Medical Center | Hackensack | New Jersey | 07601 | Withdrawn |
| Albany Medical Center | Albany | New York | 12208 | Withdrawn |
| Col Uni Med Center New York Presby | New York | New York | 10032 | Completed |
| Baylor Scott and White Research | Temple | Texas | 76502 | Withdrawn |
| University of Wisconsin | Madison | Wisconsin | 53792 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 72 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04817618, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 12, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04817618 live on ClinicalTrials.gov.